PDCD1 and neoplasm: In this trial, cisplatin and doxorubicin priming before nivolumab treatment showed a superior therapeutic response, which has been shown to be associated with the immunoregulatory features of these chemotherapeutic drugs to develop favorable tumor microenvironment for PD-1 blockers.